Posted on 12/11/2009 in Pharmaceutical Company Product News Novo Nordisk has announced that it has pledged a total of three million euros (2.71 million pounds) over the next three years to the European Foundation for the Study of Diabetes (EFSD), in a bid to support the organisation's research into the life-threatening condition.
According to the firm, diabetes is growing rapidly in Europe and the need to understand the workings of the condition is pressing.
Non-profit institutions in Europe within any area of basic or clinical diabetes research are being welcomed to apply for funding and an announcement is set to be published in the official journal of the EFSD.
The deadline for applications is April 1st 2010.
Dr Viktor Jorgens, executive director of EFSD, stated: "The programme, which will be governed by the EFSD, will support European research into understanding the cause and treatment of all forms of diabetes."
Last month, Novo Nordisk announced its financial results for the third quarter of 2009, revealing a 30 per cent increase in its operating profits, this figure rising to 11,714 million Danish kroner (1.411 billion pounds) during the period.
Other news stories from 12/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
